Sandusky, Ohio, June 17, 2021 (GLOBE NEWSWIRE) — PAO Group, Inc. (OTC Pink: PAOG) right now confirmed the corporate’s plan to launch a CBD Nutraceuticals line of merchandise anticipated to generate income this 12 months, in 2021, is on monitor. The corporate additionally continues within the long-term CBD pharmaceutical.
Subsequent week, on Wednesday, June 23rd, administration will launch an replace on the corporate’s CBD Nutraceuticals improvement initiative to incorporate new developments anticipated to broaden PAOG’s total market alternative.
The 2020 CBD Nutraceuticals Market had an estimated worth of $5.2 Billion, and it’s anticipated to succeed in $16.4 Billion by 2027.
PAOG is engaged on the event of a CBD pharmaceutical product beneath the identify RespRx, for the remedy of Continual Obstructive Pulmonary Dysfunction (COPD) derived from a patented hashish extraction technique – U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.”
PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Hashish Holdings, Inc. (OTC Pink: USMJ) as a distributor.
Be taught extra about PAOG at www.paogroupinc.com.
Ahead-Wanting Statements: Sure statements on this information launch could comprise forward-looking info inside the that means of Rule 175 beneath the Securities Act of 1933 and Rule 3b-6 beneath the Securities Change Act of 1934, and are topic to the secure harbor created by these guidelines. All statements, apart from statements of truth, included on this launch, together with, with out limitation, statements concerning potential future plans and aims of the corporate are forward-looking statements that contain dangers and uncertainties. There will be no assurance that such statements will show to be correct and precise outcomes and future occasions may differ materially from these anticipated in such statements. Technical problems, which can come up, may stop the immediate implementation of any strategically vital plan(s) outlined above. The Firm undertakes no responsibility to revise or replace any forward-looking statements to mirror occasions or circumstances after the date of this launch.